Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intron-A [interferon alpha-2b]/Aldara [imiquimod] combination therapy for BCC [basal cell carcinoma] excluding the face and scalp

Next Previous
X
Search
Trial Profile

Intron-A [interferon alpha-2b]/Aldara [imiquimod] combination therapy for BCC [basal cell carcinoma] excluding the face and scalp

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2013

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imiquimod (Primary) ; Interferon alpha-2b (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Feb 2011 Planned end date changed from May 2011 to Sep 2011 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 40 to 49 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Dec 2010 to 1 May 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top